Skip to content

STAA

NASDAQ

STAAR Surgical Co

Health Care
Health Care
Report Card

STAA at a glance — five pillars scored 0–100 from real filed financials.

Value
Growth
Profitability
0
Health
0
Dividends
0

Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.

Key Metrics

Market Cap

$0.00

P/E

Forward P/E (est.)

ROE

Revenue Growth

EPS Growth

Profit Margin

FCF Yield

Debt / Equity

ROIC

-21.0%

Interest Coverage

Current Ratio

5.12x

Dividend Yield

Implied Growth (rev. DCF)

Rating Score

0/100

Business Overview
Research

STAAR Surgical Co (STAA) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.

In its latest reported year it generated about $239.44M in revenue and posted a net loss of $80.45M.

Our model rates STAA Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.

Revenue Growth
Research

4Y CAGR

1.0%

Revenue moved from $82.43M in 2016 to $239.44M in 2026, a 14.3% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.

Profitability
0/1 checks passedROIC above 10%

Gross Margin

76.2%

Operating Margin

-38.3%

Net Margin

-33.6%

ROE

Debt Analysis
Research
1/1 checks passedShort-term bills covered

Total Debt

Net Debt

Net Debt / EBITDA

Debt / Equity

Leverage: debt-to-equity is n/a, with a current ratio of 5.1x. Detailed balance-sheet leverage is limited for this name.

Cash Flow Analysis
Research

Operating CF

-$34.23M

Free Cash Flow

-$40.05M

FCF Margin

-16.7%

In the latest year STAAR Surgical Co produced about -$34.23M of operating cash flow but negative free cash flow as it invested heavily. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.

Valuation Analysis
Research

P/E

P/S

P/B

EV / EBITDA

STAA trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.

Metrics vs. Typical Range

Where this stock sits versus what most companies trade at.

TTM P/E
Forward P/E
P/S ratio
Revenue growth
EPS growth
Gross margin
76.2%Strong
Net margin
ROE

Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.

Bull Case

The case for STAA:

  • As an established S&P 500 member in Health Care, it brings scale and a long operating history.
Bear Case

The case against STAA:

  • Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Key Risks
Research

Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.

Investment Thesis
Research

On balance, the picture is mixed: STAAR Surgical Co is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.

STAA — frequently asked questions

Is STAA a good stock to buy?

We don't give buy or sell advice. Review STAAR Surgical Co's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.

Where does STAA's data come from?

Live price data plus real fundamentals and 5-year financials pulled directly from STAAR Surgical Co's SEC filings — refreshed automatically, not hand-entered.

How is the 5-year projection for STAA calculated?

It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.

Is this STAA analysis financial advice?

No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell STAA. Always do your own research and consider a licensed professional.

Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.

Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.